Solna, Sweden, 30 June 2022 – As previously announced, Fredrik Järrsten will leave his position as Chief Financial Officer (CFO) at Vivesto. The company today announces that Robert Maiorana has been appointed acting CFO, with effect from July 1, 2022. The process of recruiting a new CFO is ongoing.
Robert has worked for Vivesto since the second half of 2020 and as Finance Manager since March 2021. He will be part of Vivesto's group management during his appointment.
Robert has extensive finance experience from senior positions. He has previously worked as a Finance and Management Consultant at Nacka Municipality and Bactiguard Holding AB and CFO at International Copyright Enterprise Services AB, ParaCell Solutions AB and MFEX Mutual Funds Exchange AB. He was also Head of Finance at Ryds Bilglas AB and ABN AMRO Bank Sweden. Robert holds a Bachelor of Science in Business and Economics from Lund University.
For More Information:
Francois Martelet, CEO
Phone: +46 18-50 54 40
Consilium Strategic Communications (For Vivesto)
Phone: +44 (0)20 3709 5700
About Vivesto AB
Vivesto is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients through a partnership with Elevar Therapeutics, Inc. Development programs include Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxel micellar, in development for advanced prostate cancer. Vivesto has proprietary drug delivery technology designed to improve solubility, efficacy and safety. Vivesto’s shares are traded on Nasdaq Stockholm (VIVE). To find out more about Vivesto please visit www.vivesto.com.